Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Neuronetics (NASDAQ: STIM), a medical technology and healthcare company focused on neurohealth therapies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Keith Sullivan, President and CEO, will deliver a presentation on Tuesday, August 12, 2025, at 1:30 PM ET.

The presentation will be accessible to registered attendees and presenting companies through the conference portal for 14 days following the event.

News Market Reaction

-2.47% 2.1x vol

15 alerts

-2.47% News Effect

-13.8% Trough in 3 hr 28 min

-$8M Valuation Impact

$308M Market Cap

2.1x Rel. Volume

On the day this news was published, STIM declined 2.47%, reflecting a moderate negative market reaction. Argus tracked a trough of -13.8% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $308M at that time. Trading volume was elevated at 2.1x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45^th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day.

The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following the event.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Investor Contact:

Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com

Media Contact:

EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

FAQ

When is Neuronetics (STIM) presenting at the Canaccord Genuity Growth Conference?

Neuronetics will present on Tuesday, August 12, 2025, at 1:30 PM Eastern Time.

Who will be presenting for Neuronetics at the Canaccord Conference?

Keith Sullivan, President and Chief Executive Officer of Neuronetics, will be presenting at the conference.

How long will the Neuronetics (STIM) presentation be available after the conference?

The presentation will be available to registered attendees and presenting companies for 14 days following the event through the conference portal.

What is Neuronetics' (STIM) main business focus?

Neuronetics is a medical technology and healthcare company specializing in neurohealth therapies, focused on transforming patient lives with leading treatments.